ENVB (Enveric Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ENVB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-03 | Peter J. Facchini | Chief Innovation Officer | A | — | — |
| 2026-06-03 | Kevin Michael Coveney | Chief Financial Officer | A | — | — |
| 2026-06-03 | Marcus Schabacker | Director | A | — | — |
| 2026-06-03 | Sheila DeWitt | Director | A | — | — |
| 2026-06-03 | Joseph Edward Tucker | Chief Executive Officer | A | — | — |
| 2026-06-03 | MICHAEL D WEBB | Director | A | — | — |
| 2026-06-03 | FRANK PASQUALONE | Director | A | — | — |
| 2026-06-03 | George A. Kegler | Director | A | — | — |
| 2025-12-30 | Joseph Edward Tucker | Chief Executive Officer | A | — | — |
| 2025-12-30 | FRANK PASQUALONE | Director | A | — | — |
| 2025-12-30 | MICHAEL D WEBB | Director | A | — | — |
| 2025-12-30 | Kevin Michael Coveney | Chief Financial Officer | A | — | — |
| 2025-12-30 | Sheila DeWitt | Director | A | — | — |
| 2025-12-30 | George A. Kegler | Director | A | — | — |
| 2025-12-30 | Marcus Schabacker | Director | A | — | — |
| 2025-05-12 | Kevin Michael Coveney | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-05-12 | Peter J. Facchini | CHIEF INNOVATION OFFICER | A | — | — |
| 2025-05-12 | Joseph Edward Tucker | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2024-10-11 | Peter J. Facchini | CHIEF INNOVATION OFFICER | A | — | — |
| 2024-10-11 | Sheila DeWitt | Director | A | — | — |
| 2024-10-11 | FRANK PASQUALONE | Director | A | — | — |
| 2024-10-11 | Marcus Schabacker | Director | A | — | — |
| 2024-10-11 | Kevin Michael Coveney | CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-10-11 | Joseph Edward Tucker | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2024-10-11 | George A. Kegler | Director | A | — | — |
| 2024-10-11 | MICHAEL D WEBB | Director | A | — | — |
| 2024-02-26 | Joseph Edward Tucker | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2024-02-26 | Peter J. Facchini | CHIEF INNOVATION OFFICER | A | — | — |
| 2024-02-26 | Kevin Michael Coveney | CHIEF FINANCIAL OFFICER | A | — | — |
| 2023-09-19 | FRANK PASQUALONE | Director | Buy | — | — |
| 2023-03-14 | Kevin Michael Coveney | Chief Financial Officer | A | — | — |
| 2023-01-27 | Avani Kanubaddi | President and COO | A | — | — |
| 2023-01-27 | Joseph Edward Tucker | Chief Executive Officer | A | — | — |
| 2023-01-27 | Jillian Marie Hagel | Vice President of Innovation | A | — | — |
| 2023-01-27 | Peter J. Facchini | Chief Innovation Officer | A | — | — |
| 2023-01-25 | Joseph Edward Tucker | Chief Executive Officer | A | — | — |
| 2023-01-25 | Jillian Marie Hagel | Chief Technology Officer | A | — | — |
| 2023-01-25 | Peter J. Facchini | Chief Scientific Officer | A | — | — |
| 2022-01-25 | Carter Julian Ward | Chief Financial Officer | A | — | — |
| 2022-01-25 | Avani Kanubaddi | President and COO | A | — | — |
| 2021-10-18 | Jillian Marie Hagel | Chief Technology Officer | A | — | — |
| 2021-10-15 | Peter J. Facchini | Chief Scientific Officer | A | — | — |
| 2021-10-12 | Joseph Edward Tucker | Chief Executive Officer | A | — | — |
| 2021-09-27 | Bradley George Thompson | Director | A | — | — |
| 2021-09-27 | Joseph Edward Tucker | Chief Executive Officer | A | — | — |
| 2021-04-02 | DOUGLAS LIND | Director | A | — | — |
| 2021-03-08 | John Van Buiten | Chief Financial Officer | A | — | — |
| 2021-02-17 | Avani Kanubaddi | Chief Operating Officer | A | — | — |
| 2021-02-17 | Marcus Schabacker | Director | A | — | — |
| 2021-02-17 | David Ian Johnson | CEO and Chairman | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 271,556 | — |
| — | Chief Financial Officer | 180,746 | — |
| — | Chief Innovation Officer | 27,814 | — |
| — | Director | 26,423 | — |
| — | Director | 26,418 | — |
| — | Director | 26,418 | — |
| — | Director | 26,416 | — |
| — | Director | 26,306 | — |
| — | President and COO | 269 | — |
| — | Vice President of Innovation | 258 | — |
| — | Chief Financial Officer | 3 | — |
| — | Director | 2 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ENVB quote page; the site-wide leaderboard is on the insider transactions hub.